Biogen: Alzheimer’s drug ‘unlikely’ to get EMA approval

Biogen Idec was notified by a European Medicines Agency (EMA) panel of experts that its Alzheimer’s treatment Aduhelm is “unlikely” to win their approval, the United States biotechnolo…